[
  {
    "ts": null,
    "headline": "Sector Update: Health Care Stocks Advance in Afternoon Trading",
    "summary": "Health care stocks rose Monday afternoon, with the NYSE Health Care Index up 0.5% and the Health Car",
    "url": "https://finnhub.io/api/news?id=23dcd43d4d13da9d5009b05da5a2c895470d9290d173e98ec9ea32586b5a76e6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764009981,
      "headline": "Sector Update: Health Care Stocks Advance in Afternoon Trading",
      "id": 137592695,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "Health care stocks rose Monday afternoon, with the NYSE Health Care Index up 0.5% and the Health Car",
      "url": "https://finnhub.io/api/news?id=23dcd43d4d13da9d5009b05da5a2c895470d9290d173e98ec9ea32586b5a76e6"
    }
  },
  {
    "ts": null,
    "headline": "Novo's $5 Billion Alzheimer's Dream Just Died--And Investors Are Cratering the Stock",
    "summary": "A long-shot Ozempic trial collapse sends Novo Nordisk to its lowest levels since 2021, reigniting market fears.",
    "url": "https://finnhub.io/api/news?id=2b0351106e5d56c3528387343c5f0c530bc138273a1eab30d887f00ab014f53e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764002785,
      "headline": "Novo's $5 Billion Alzheimer's Dream Just Died--And Investors Are Cratering the Stock",
      "id": 137591351,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "A long-shot Ozempic trial collapse sends Novo Nordisk to its lowest levels since 2021, reigniting market fears.",
      "url": "https://finnhub.io/api/news?id=2b0351106e5d56c3528387343c5f0c530bc138273a1eab30d887f00ab014f53e"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk Stock Falls. Why Its Alzheimer’s Trial News Is Hitting Shares.",
    "summary": "The drugmaker says an oral version of Wegovy improved Alzheimer’s-related biomarkers, but didn’t delay the disease’s progression.",
    "url": "https://finnhub.io/api/news?id=8db803eabb3897db25a0b11f419e9bd28d0f8ef63d1ed0b9172421bcb672532d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764002040,
      "headline": "Novo Nordisk Stock Falls. Why Its Alzheimer’s Trial News Is Hitting Shares.",
      "id": 137591352,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "The drugmaker says an oral version of Wegovy improved Alzheimer’s-related biomarkers, but didn’t delay the disease’s progression.",
      "url": "https://finnhub.io/api/news?id=8db803eabb3897db25a0b11f419e9bd28d0f8ef63d1ed0b9172421bcb672532d"
    }
  },
  {
    "ts": null,
    "headline": "Novo Dives After Weight-Loss Pill Fails In Alzheimer's Disease; Biogen Jumps",
    "summary": "Novo Nordisk stock plummeted Monday after its weight-loss pill failed to significantly slow the progression of Alzheimer's disease in two big studies.",
    "url": "https://finnhub.io/api/news?id=94f7b64989500bd7e1381721cd92f277e57f42e0761ae5339a77dc699987aa86",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763994209,
      "headline": "Novo Dives After Weight-Loss Pill Fails In Alzheimer's Disease; Biogen Jumps",
      "id": 137591355,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "Novo Nordisk stock plummeted Monday after its weight-loss pill failed to significantly slow the progression of Alzheimer's disease in two big studies.",
      "url": "https://finnhub.io/api/news?id=94f7b64989500bd7e1381721cd92f277e57f42e0761ae5339a77dc699987aa86"
    }
  },
  {
    "ts": null,
    "headline": "Biogen to gain from Novo Nordisk Alzheimer’s failure, says Jefferies",
    "summary": "Investing.com -- Biogen shares could benefit from Novo Nordisk’s Phase III Evoke/Evoke+ trials failure, according to analysts at Jefferies.",
    "url": "https://finnhub.io/api/news?id=044438f505aaec20c33cf202b8ced1a808caa025abe6d85b0648017fdaabdac2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763994175,
      "headline": "Biogen to gain from Novo Nordisk Alzheimer’s failure, says Jefferies",
      "id": 137591797,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "Investing.com -- Biogen shares could benefit from Novo Nordisk’s Phase III Evoke/Evoke+ trials failure, according to analysts at Jefferies.",
      "url": "https://finnhub.io/api/news?id=044438f505aaec20c33cf202b8ced1a808caa025abe6d85b0648017fdaabdac2"
    }
  },
  {
    "ts": null,
    "headline": "Stock Market Today: Dow Jones Rises; Google Pops On Salesforce Praise, Novo Nordisk Dives",
    "summary": "Futures rose Monday. Google popped amid Salesforce CEO Marc Benioff's praise for AI model Gemini 3. Novo Nordisk dived on Alzheimer's trial data.",
    "url": "https://finnhub.io/api/news?id=1713a63a213910d70e580be329b7217c1d094b7eeeab080ffbb78c397655cc5f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763991036,
      "headline": "Stock Market Today: Dow Jones Rises; Google Pops On Salesforce Praise, Novo Nordisk Dives",
      "id": 137589046,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "Futures rose Monday. Google popped amid Salesforce CEO Marc Benioff's praise for AI model Gemini 3. Novo Nordisk dived on Alzheimer's trial data.",
      "url": "https://finnhub.io/api/news?id=1713a63a213910d70e580be329b7217c1d094b7eeeab080ffbb78c397655cc5f"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk Dives As Ozempic Fails To Slow Alzheimer's; Lilly Falls, Biogen Jumps",
    "summary": "Novo Nordisk reported Monday that a Ozempic pill failed to slow the progression of Alzheimer's in two big studies. Novo dived, Eli Lilly fell. Biogen rose.",
    "url": "https://finnhub.io/api/news?id=923dcc45527f789e33996e4c3cc174572fef8802d93778210e16f31c20a18743",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763990394,
      "headline": "Novo Nordisk Dives As Ozempic Fails To Slow Alzheimer's; Lilly Falls, Biogen Jumps",
      "id": 137589129,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "Novo Nordisk reported Monday that a Ozempic pill failed to slow the progression of Alzheimer's in two big studies. Novo dived, Eli Lilly fell. Biogen rose.",
      "url": "https://finnhub.io/api/news?id=923dcc45527f789e33996e4c3cc174572fef8802d93778210e16f31c20a18743"
    }
  },
  {
    "ts": null,
    "headline": "Versant Ventures Announces Launch of Dayra Therapeutics With Foundational Biogen Partnership",
    "summary": "TORONTO & CAMBRIDGE, Mass., November 24, 2025--Versant Ventures today announced the launch of Dayra Therapeutics, a startup focused on developing oral macrocyclic peptides for a range of serious diseases. The company has secured more than $70 million in committed funding, including a collaboration with Biogen Inc. that will provide $50 million in upfront capital, as well as an equity commitment from Versant.",
    "url": "https://finnhub.io/api/news?id=ff51de13240e092c8d6959aea1e4378a85511a73c3e087129844f7ace38e1748",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763987400,
      "headline": "Versant Ventures Announces Launch of Dayra Therapeutics With Foundational Biogen Partnership",
      "id": 137589367,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "TORONTO & CAMBRIDGE, Mass., November 24, 2025--Versant Ventures today announced the launch of Dayra Therapeutics, a startup focused on developing oral macrocyclic peptides for a range of serious diseases. The company has secured more than $70 million in committed funding, including a collaboration with Biogen Inc. that will provide $50 million in upfront capital, as well as an equity commitment from Versant.",
      "url": "https://finnhub.io/api/news?id=ff51de13240e092c8d6959aea1e4378a85511a73c3e087129844f7ace38e1748"
    }
  },
  {
    "ts": null,
    "headline": "Biogen and Dayra Therapeutics Announce Research Collaboration to Discover and Develop Oral Macrocyclic Peptides for a Range of Immunological Conditions",
    "summary": "Oral macrocyclic peptides have the potential to offer biologic-like efficacy and safety in a convenient oral formatCollaboration further advances Biogen’s immunology strategy by broadening its early-stage pipeline and incorporating an additional clinically validated modality into its expanding immunology capabilities CAMBRIDGE, Mass. and TORONTO, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Dayra Therapeutics today announced a research collaboration to discover and develop or",
    "url": "https://finnhub.io/api/news?id=d9538f1fd662e6f889aca9b513a66040e61be1f7c47490504bfcacf7dfded3ff",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763987400,
      "headline": "Biogen and Dayra Therapeutics Announce Research Collaboration to Discover and Develop Oral Macrocyclic Peptides for a Range of Immunological Conditions",
      "id": 137589366,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "Oral macrocyclic peptides have the potential to offer biologic-like efficacy and safety in a convenient oral formatCollaboration further advances Biogen’s immunology strategy by broadening its early-stage pipeline and incorporating an additional clinically validated modality into its expanding immunology capabilities CAMBRIDGE, Mass. and TORONTO, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Dayra Therapeutics today announced a research collaboration to discover and develop or",
      "url": "https://finnhub.io/api/news?id=d9538f1fd662e6f889aca9b513a66040e61be1f7c47490504bfcacf7dfded3ff"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk shares plunge after Alzheimer's drug trial fails to hit key target",
    "summary": "Shares of Novo Nordisk plunged after the Danish pharmaceutical company said a highly anticipated trial for Alzheimer's disease failed to meet its main goal.",
    "url": "https://finnhub.io/api/news?id=fe0d2bb1dcd6197f56c7ca541276872d09bf9d22b8550b1bf082818e17649254",
    "source": "CNBC",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763966481,
      "headline": "Novo Nordisk shares plunge after Alzheimer's drug trial fails to hit key target",
      "id": 137590978,
      "image": "https://image.cnbcfm.com/api/v1/image/108178404-17537973702025-07-29t124507z_1311503085_rc2bmfaaroie_rtrmadp_0_novo-nordisk.jpeg?v=1753891974&w=1920&h=1080",
      "related": "BIIB",
      "source": "CNBC",
      "summary": "Shares of Novo Nordisk plunged after the Danish pharmaceutical company said a highly anticipated trial for Alzheimer's disease failed to meet its main goal. ",
      "url": "https://finnhub.io/api/news?id=fe0d2bb1dcd6197f56c7ca541276872d09bf9d22b8550b1bf082818e17649254"
    }
  }
]